Related Experiment Video
Updated: Jun 1, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Commentary on symptom experience of pulmonary arterial hypertension (PAH) patients
1King’s College London, UK. eu.khan@kcl.ac.uk
Abstract:
Pulmonary arterial hypertension (PAH) is a complex and rapidly progressing illness with few long-term treatment options to prolong life and improve quality of life. The complexity of the disease predisposes patients to a multitude of symptoms that have an effect on their biopsychosocial well-being. McDonough et al. have taken a qualitative approach to examine the dimensions of PAH symptomology. Using a telephone survey approach, 10 patients were questioned regarding their symptoms. Following coding and categorization of the responses, two main themes were found, "holding back" and redefining life.” The primary symptom associated with holding back was breathlessness. This symptom largely governed fears and behaviors associated with subthemes found within this main theme. Breathlessness also featured in the redefining life category; however, practical issues associated with medication and treatment were also assigned importance in this category by the study respondents. Symptoms of anxiety and depression were counteracted in many instances by a positive and sometimes stoic attitude toward the illness. This study presents important foundational information which will help direct further development of theoretical hypothesis related to PAH symptomology, as well as help focus clinical research toward venues that will enhance nursing care of this complex disease.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pneumonia II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

